News & Updates
Filter by Specialty:
TYK2 inhibitor for psoriatic arthritis clears phase II trial
In the treatment of patients with psoriatic arthritis, the use of the selective TYK2 inhibitor deucravacitinib appears to be effective and well tolerated, leading to greater improvements in American College of Rheumatology (ACR) domains, enthesitis endpoints, and multiple patient-reported, psoriasis-related outcomes relative to placebo, as shown in the results of a phase II trial.
TYK2 inhibitor for psoriatic arthritis clears phase II trial
26 Mar 2022
TNFi use does not induce hypertension in ankylosing spondylitis
Use of tumour necrosis factor inhibitor (TNFi) does not appear to contribute to incident hypertension in individuals with ankylosing spondylitis (AS), reports a study.
TNFi use does not induce hypertension in ankylosing spondylitis
25 Mar 2022
Electronic, mobile health interventions improve JIA management
Harnessing electronic (eHealth) and mobile health (mHealth) interventions appears to be an efficient way of supplementing the management of juvenile idiopathic arthritis (JIA), as shown by the results of a systematic review and meta-analysis.
Electronic, mobile health interventions improve JIA management
22 Mar 2022
Colchicine touted for prevention of gout flare-ups after COVID-19 vaccination
Gout patients have about sixfold greater odds of experiencing a flare in the first few months after COVID-19 vaccination, but colchicine appears to keep these gout attacks at bay, as shown in a study from China.
Colchicine touted for prevention of gout flare-ups after COVID-19 vaccination
18 Mar 2022
New NSAID patch matches diclofenac gel for pain management in knee osteoarthritis
The novel topical nonsteroidal anti-inflammatory drug (NSAID) S-flurbiprofen plaster provides relief from pain that appears similar to that achieved with diclofenac gel in patients with knee osteoarthritis, in addition to being well tolerated, according to data from an open-label, noninferiority phase III study.
New NSAID patch matches diclofenac gel for pain management in knee osteoarthritis
09 Mar 2022
Selective TYK2 inhibitor safe, works against psoriatic arthritis
Deucravacitinib, a selective TYK2 inhibitor, is well tolerated and appears to produce marked improvements in American College of Rheumatology 20 (ACR20) and other endpoints in the treatment of patients with psoriatic arthritis (PsA), according to the results of a phase II study.
Selective TYK2 inhibitor safe, works against psoriatic arthritis
08 Mar 2022
Schizophrenia genetics not linked to neuropsychiatric features in childhood-onset SLE
No apparent association exists between neuropsychiatric systemic lupus erythematosus (NPSLE) and known risk loci for schizophrenia in a multiethnic cohort of patients with childhood-onset (c)SLE, reveals a recent study.
Schizophrenia genetics not linked to neuropsychiatric features in childhood-onset SLE
28 Feb 2022
Sarcoidosis patients at risk of haematologic, nonmelanoma skin cancers
Sarcoidosis patients with biopsy-verified non-necrotizing granulomatous inflammation are at greater risk of haematologic cancers and nonmelanoma skin cancer (NMSC) in the long term than the general population, a study has found.